Write in a clean editor, then format for Statistics in Biopharmaceutical Research in one click — DocuGuru applies the official Taylor & Francis template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Statistics in Biopharmaceutical Research is a peer-reviewed journal published by Taylor & Francis, covering Statistical Methods in Clinical Trials, Advanced Causal Inference Techniques, Health Systems, Economic Evaluations, Quality of Life. Over its lifetime it has published 1,020 papers, which have received 7,488 citations.
| Publisher | Taylor & Francis |
|---|---|
| Reference style | Author–year (Chicago, T&F) Author–year — (Smith, 2023) in the text Smith, Ada, Ben Jones, and Cara Lee. 2023. "A Representative Article Title." Statistics in Biopharmaceutical Research 12 (3): 45–58.
Formats any DOI in Statistics in Biopharmaceutical Research style. No sign-up. |
| Publishes research in | Statistical Methods in Clinical Trials Advanced Causal Inference Techniques Health Systems, Economic Evaluations, Quality of Life Optimal Experimental Design Methods Statistical Methods and Bayesian Inference |
| ISSN | 1946-6315 |
| Citation impact (2-yr) | 1.03 |
| h-index | 38 |
| i10-index | 208 |
| Top institutions publishing here | Novartis (Switzerland) |
| Journal website | www.tandfonline.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
To test the anticancer effect of combining two drugs targeting different biological pathways, the popular way to show synergistic effect of drug combination is a heat map or surface plot based on the percent excess the Bliss prediction using the average response measures at each combination dose. Such graphs, however, are inefficient in the drug…
In the future, clinical trials will have an increased emphasis on pragmatism, providing a practical description of the effects of new treatments in realistic clinical settings. Accomplishing pragmatism requires better summaries of the totality of the evidence in ways that clinical trials consumers—patients, physicians, insurers—find transparent and allow for informed benefit:risk decision-making.The current approach to…
Abstract In 1997, Robert T. O'Neill introduced the framework of structuring the experimental questions to best reflect the clinical study's objectives. This task comprises the identification of the study's primary, secondary, and exploratory objectives and the requirements as to when the corresponding statistical tests are considered meaningful. A topic that has been considered much less…
The log-rank test is most powerful under proportional hazards (PH). In practice, non-PH patterns are often observed in clinical trials, such as in immuno-oncology; therefore, alternative methods are needed to restore the efficiency of statistical testing. Three categories of testing methods were evaluated, including weighted log-rank tests, Kaplan–Meier curve-based tests (including weighted Kaplan–Meier and restricted…
The National Research Council (NRC) highlighted the need to more clearly distinguish between the target of estimation (“estimand”) and the method of estimation (“estimator”) in clinical trials. While the NRC report on “The Prevention and Treatment of Missing Data in Clinical Trials” focuses on issues arising due to missing data, a framework to coherently align…
